Burgess et al. HCA Healthcare Journal of Medicine (2021) 2:2
https://doi.org/10.36518/2689-0216.1269

Clinical Review
COVID-19: The Vaccine Race Continues
L. Hayley Burgess, PharmD, MBA, BCPP, CPPS,1
Carley Castelein, PharmD, BCPS,CPPS,1 Andrew Rubio, PharmD,1
Mandelin K. Cooper, PharmD, BCPS1

Abstract

Author affiliations are listed
at the end of this article.
Correspondence to:
L. Hayley Burgess, PharmD,
MBA, BCPP, CPPS

Description

Over a year has passed since the discovery of SARS-CoV-2 and the subsequent COVID-19
pandemic. As mitigation efforts continue, COVID-19 has claimed over half a million lives in
the United States and 3.1 million lives globally. The development and availability of vaccines
delivering immunity to prevent COVID-19 offers hope to end the pandemic.
Emergency use authorizations from the Food and Drug Administration have been issued in
the United States for three vaccines, one each from Pfizer-BioNTech, Moderna and Janssen/J&J. Pfizer-BioNTech and Moderna are both mRNA vaccines with efficacy of 95% and
94.1% respectively, while the vector-based vaccine from Janssen/J&J has an overall efficacy
of 66.1%. The Janssen/J&J vaccine, having received the most recent authorization, is an
attractive option due to high efficacy with a single dose.
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With a high immunity rate of 70–80% needed to prevent the continued spread of the virus
and mutations, the majority of the population will require vaccination. The rise of mutations
from selective pressure has further increased the urgency. Recent discoveries of variants
have led to uncertainties regarding the impact of immunity and effectiveness of vaccines.
In order to end the global pandemic, it is essential that the Centers for Disease Control and
World Health Organization monitor the variant potential and educate the public appropriately to encourage appropriate vaccination and allocation of product.
Achieving high vaccination rates in the U.S. has been challenged by supply, storage requirements and public hesitancy. In a recent Gallup poll, a random sample of 4,098 adults demonstrated that 71% of survey respondents were willing to receive a vaccine, which remains
on the lower end of the 70–80% vaccination range required to end this pandemic. Despite
these challenges, the United States has managed to surpass 225 million vaccinations.
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Introduction

Global efforts to control coronavirus disease
2019 (COVID-19) infections developed from
severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have led to emergency use authorizations (EUA) in the United States (U.S.)
for three vaccines and laid the production
pipeline for several others. Although infection
prevention strategies such as social distancing,
closings of schools and offices, stay at home
orders, mask mandates and capacity limitations
have been implemented, as of April 25, 2021,

COVID-19 has surpassed 572,199 deaths in the
U.S. and 3.1 million deaths worldwide.1 Current COVID-19 medication treatment strategies provided mixed results, leaving our most
promising avenue of ending this pandemic with
vaccines.
The race to develop a safe and effective vaccine has contenders from multiple manufacturers globally, but is threatened not only by
the hesitancy of the public, but also by recent
SARS-CoV-2 variants. Immunity in 70–80%
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of the population has been projected to stop
COVID-19 spread and mutations.2 Public polling results of willingness to receive the vaccine
have been mixed. A U.S. Census Bureau survey
of 68,000 adults from January 6 to 18, 2021, revealed only 51% of respondents would definitely receive the vaccine.2,3 Fortunately, the data
from other surveys later in January showed
that public support to receive a vaccine is
growing, with an increased population reporting they would receive the vaccine as soon as
it is available.4,5 Gallup poll results continued to
improve in February 2021 with the highest rate
of vaccine acceptance at 71%. The challenges of
public acceptance of the vaccine coupled with
the recent reports of mutations in the United
Kingdom (UK), South Africa, Brazil and the U.S.
are a critical concern.

Vaccine Approval Status

At the time of publication, three vaccines have
been granted EUA approval by the Food and
Drug Administration (FDA), 91 vaccines are in
clinical development and 184 vaccines are in the
pre-clinical development process worldwide.6-10
As of April 24, 2021, the U.S. has administered
over 225 million doses of COVID-19 vaccines
with 93 million people being fully vaccinated.11,12
Each vaccine has specific storage requirements
that are important considerations for administration sites. The Pfizer-BioNTech COVID-19
vaccine requires temperatures between -80°C
to -60°C prior to dilution, while the Moderna COVID-19 vaccine requires temperatures

82

Cansino

Jassen/
J&J

Bharat

Novavax

between -25°C to -15°C with resultant efficacies of 95% and 94.1% respectively.10,13 Recently, the FDA has allowed the Pfizer-BioNTech
COVID-19 vaccine to be stored at -25°C to -15°C
for up to two weeks after data was submitted
to support stability at this temperature. Unlike
the mRNA vaccines, which have freezer storage
requirements, vector-based vaccine candidates
are able to be stored at refrigerated temperatures.15,16 However, vector-based vaccines have
shown reduced rates of efficacy: 70.4% for AstraZeneca/Oxford and 66.1% for Janssen/Johnson and Johnson (J&J).9,10,13-16 Janssen/J&J’s
vector-based vaccine was submitted for EUA
in the U.S. on February 4, 2021, and received
approval on February 27, 2021, based on phase 3
data demonstrating that this single-dose vaccine met its primary and secondary endpoints.17
Outside of the U.S., alternative vaccines are
available in various stages of approval. (Table
1) Phase 3 data has been made available for
AstraZeneca/Oxford’s vector-based vaccine,
which has been approved for emergency supply
in the UK.15,16 Another notable vector-based
vaccine is Gamaleya’s Sputnik V, which utilizes
a combination of two adenoviruses rAd5 and
rAd26, with 91.2% efficacy. Russia approved
Sputnik V on August 11, 2020, prior to completion of phase 3 trials.18 China has multiple
COVID-19 vaccines available, including Convidecia by CanSino Biologics with 65.7% efficacy,
BBIBP-CorV by Sinopharm with 79.34% efficacy, CoronaVac by Sinovac Biotech with 50.38%
efficacy, and Sinopharm-Wuhan by the Wuhan

Burgess et al. (2021) 2:2. https://doi.org/10.36518/2689-0216.1269

Institute of Biological Products. India currently
has Covaxin by Bharat Biotech, although its
efficacy is unknown.19

Viral Vector Technology Implications
for COVID-19 Vaccines

Viral vector vaccines were first introduced in
the 1970s and have also been studied for gene
therapy, cancer treatments and molecular
biology research. Viral vector vaccines have
also been used against a variety of infectious
diseases including Zika virus, influenza viruses,
respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), malaria and Ebola.19-23
Vector vaccines use a different virus than the
targeted virus to trigger an immune response.
For example, AstraZeneca/Oxford and Janssen/J&J’s COVID-19 vaccines utilize a modified
adenovirus vector, based on the common cold,
to deliver a gene to human immune cells that
triggers an immune response.20,23,24 The adenovirus is modified and inserted with genetic
material for antigens against SARS-CoV-2
antigen spike proteins. The spike protein is a
transmembrane protein specific to the SARSCoV-2 virus and is found on the surface. Once
the gene enters the human cell, the viral vector
will use the cell’s processes to develop a spike
protein and lead the body’s immune system to
believe it is infected with COVID-19. When the
cells are infected and instructed to make large
amounts of antigen, they trigger an immune
response, similar to what happens during a
natural infection. This subsequently triggers
a strong immune response by T cells and the
production of antibodies by B cells.
One concern of using viral vectors is the recipient may have been exposed to the vector prior,
leading to pre-existing immunity. Adenoviral
vectors are based on natural viruses (e.g., common cold) that some people may have already
been exposed to and may lead to the vaccine
not working for everyone.24,25 Scientists have
worked to overcome this issue by utilizing uncommon viruses or viruses found in other species. The AstraZeneca/Oxford vaccine utilized
a chimpanzee adenovirus and the Janssen/J&J
vaccine used a replication-incompetent human adenovirus.15,17 Adenoviruses are attractive
vectors for vaccines as their genome has been
well-studied and they induce a robust immune
response. In addition, adenoviral vector vac-

cines are well-suited for pandemic responses as
they are easy to design and produce at scale.24
Adenoviral vector vaccines have been used
during Ebola outbreaks and two recent vaccines were used in West Africa and the Democratic Republic of Congo. The technology has
also been used to develop an oral rabies vaccine
used in wild animals.24

Findings

Vaccine Trial Efficacy

With a minimum threshold for efficacy set at
50% by the FDA and World Health Organization (WHO), the approved Pfizer-BioNTech and
Moderna mRNA vaccines exceeded expectations at 95% and 94.1% efficacy against symptomatic COVID-19 infection respectively.26,27 The
Janssen/J&J vector vaccine has demonstrated
an overall efficacy of 66.1% in preventing moderate to severe COVID-19.17 There have been
three other promising viral vector-based vaccine candidates in the pipeline, two from Merck
and one from AstraZeneca/Oxford. (Figure 1)
Merck, also known as MSD outside of the U.S.
and Canada, made the decision to discontinue
the development of both of their vector-based
SARS-CoV-2/COVID-19 vaccines on January 25,
2021, and move to focus efforts on COVID-19
therapeutic treatment agents.15,28
The AstraZeneca/Oxford’s ChAdOx1 nCoV-19
(AZD1222) vaccine demonstrated 90.0% efficacy (95% CI 67.4, 97.0) in phase 3 trials when
given as a half dose followed by a full dose, and
62.1% efficacy (95% CI 41.0, 75.7) when two full
doses were administered.15 Of note, the trial
COV001 (UK) was intended as a single dose
study yet a small subgroup received a second dose at 28 days. COV002 (UK) intended
a second dose at 28 days yet many received
their vaccine after. COV003 (Brazil) offered a
second dose at up to 12 weeks with a target of
4 weeks. And COV005 (South Africa) administered a second dose at 28 days. Interestingly, the more effective regimen was based on
participants who mistakenly received a half
dose of the vaccine followed by a full dose.
These results have yet to be fully explained
by the company, although it is theorized to
have been highly efficacious due to the longer
prime-boost interval.29,30 Of note, the safety
and efficacy of AstraZeneca/Oxford’s vector
vaccine candidate against SARS-CoV-2 data
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Janssen/J&J

AstraZeneca/Oxford
Name: AZD1222

Name: Ad26.COV2.S

Vaccine Type: Vector-based

Vaccine Type: Vector-based

Route of Administration: IM

Route of Administration: IM

Storage: Refrigerator (2 to 8 °C) for up to 6 months

Storage: Refrigerator (2 to 8 °C) for up to 3 months

Dose: Multi-dose vial (10 doses)

Dose: Multi-dose vial (5 doses)

U.S. Commitments: 300 million doses

U.S. Commitments: 100 million doses

Projected Availability: 2021

Availability: March 2021

Projected EUA: 2021

EUA Approved: February 27, 2021

Investigational Status: Phase 3

Investigational Status: Phase 3

Number of Doses: 2

Number of Doses: 1 dose approved in EUA;

Timing of Doses: 0, 28 days

2 doses being studied in ENSEMBLE 2

Efficacy: 90% when given as a ½ dose followed by a
full dose and 62% when two full doses administered

Timing of Doses: 0
Efficacy: 66.1%

Figure 1. Vector-based COVID-19 Vaccines
combines results of four randomized controlled
trials from Brazil, South Africa and two from
the UK, reporting an overall efficacy of 70.4%
(95.8% CI 54.8, 80.6). A combined total of
11,636 participants were included in the interim primary efficacy analysis. Among these
patients, 131 of the 5807 participants (0.5%)
in the treatment group and 101 of the 5,829
participants (1.7%) in the placebo group had
nucleic acid amplification test (NAAT)-confirmed COVID-19 after 21 days. This vaccine also
demonstrated a satisfactory safety profile with
no statistically significant difference in serious
adverse events between the treatment (n=79)
and control (n=89) groups. In the UK phase 1/2
study, there was a case of hemolytic anemia in
the control group and a case of transverse myelitis 14 days after the ChAdOx1 nCoV-19 booster in the treatment group. In South Africa,
there was a reported serious adverse event in
the treatment group with a fever of 40°C, who
recovered without hospital admission. The UK
Medicines and Healthcare Products Regulatory
Agency authorized AstraZeneca/Oxford’s vaccine for emergency supply administered as two
full doses four to 12 weeks apart on December
30, 2020.16
The Janssen Pharmaceuticals of Johnson
and Johnson (J&J) adenovirus-based vaccine
(Ad26.CoV2.S) demonstrated in its phase 3 trial
that a single dose met all primary and second84

ary endpoints at day 14 and day 28. The trial,
ENSEMBLE, was a multicenter, international,
randomized, double-blind, placebo-controlled
trial with 44,325 participants randomized to
receive either a single dose of Ad26.CoV2.S or a
placebo.17 This vaccine demonstrated an overall
efficacy of 66.1% (95% CI 55, 74.8) in preventing moderate to severe COVID-19. Ad26.CoV2.S
was 72% effective against moderate and severe
disease at 28 days in the U.S., with 66% and
57% effectiveness in Latin America and South
Africa respectively. ENSEMBLE also demonstrated the vaccine had an efficacy of 85.4%
(95% CI 54.2, 96.9) against severe/critical
COVID-19 disease at 28 days with a reduction in
the risk of severe disease and a 100% reduction
in hospitalization or death. Janssen/J&J filed
for EUA in the U.S. and after approval, distribution began immediately. Janssen/J&J has
agreed to provide 20 million doses by the end
of March and 100 million doses by the end of
June to add to the 300 million doses promised
by Pfizer-BioNTech and Moderna by the end
of July.31-33 Janssen/J&J is currently recruiting
for a second clinical trial (ENSEMBLE 2) to
evaluate the safety and efficacy of a two-dose
vaccine compared to a placebo.32 This will also
be a multi-center, international, randomized,
double-blind, placebo-controlled trial. Of note,
Janssen/J&J has made a statement that there
are no intentions for profit to be made off the
pandemic for the company.33 Safety and ef-
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ficacy data will continue to be obtained with
ongoing trials and required Vaccine Adverse
Event Reporting System reports as outlined in
the EUA.

Vaccine Hesitancy

Immunity from 70–80% of a region’s population has been projected to stop the spread
and mutations from COVID-19. A Gallup poll of
4,098 random sampling of adults at the end of
January 2021, showed the highest rate of U.S.
adults willing to be vaccinated on record at
71%. This is up from a low of 50% in September 2020. This 71% also includes 9% of adults
who have already received the vaccine. If this
rate of vaccination comes to fruition, it may be
possible to reach the lower proposed threshold of herd immunity to stop the spread of
COVID-19.34
The public’s acceptance to receive COVID-19
vaccines appears to be based on the perceived
benefits in which the unknown long-term effects outweigh the immediate impact on daily
life and movement to end the pandemic. Interestingly, public and expert perceptions may not
align. For example, the public may have expectations that the vaccine provides immunity
against the virus, and will also have an immediate impact on their daily life. When people are
asked about why they would take the vaccine,
75% responded “to feel safe around other
people” and 52% said, “It would allow me to go
back to normal activities like work or school.” 35
Fortunately, based on recommendations from
the Centers for Disease Control and Prevention
(CDC), after someone is fully vaccinated they
may meet without masks in small groups with
others who are fully vaccinated.36
Among those hesitant to get the vaccine, safety is often cited as a reason. Similar to efficacy
there is a misalignment in the viewpoints of the
medical community and the public. All of the
FDA EUA approved vaccines have demonstrated safety, but 71% of the public is concerned
about the side effects and 57% have concerns
regarding the development and approval process.34 As health care providers, one important
piece of data from polls shows that health care
professionals including doctors, nurses and
pharmacists are the most trusted source of
vaccine information for the public at 58%, with
the CDC at 46% and the pharmaceutical companies lagging behind at 20%.35

The battle against vaccine hesitancy is not over
but the likelihood of successful vaccination
rates to stop this pandemic is becoming possible. As health care providers, we can support
our patients, family, and friends with their
questions and assist them in having accurate,
scientific information with which to make their
decisions.

Resistance and Mutant Strains

Viral resistance is well documented in other
infections outside of SARS-CoV-2 and has
made response to therapies difficult. The rise
of variants specifically among SARS-CoV-2
increases concern due to increased transmissibility, causing more severe disease, evading
viral diagnostic tests, reduced effectiveness of
therapeutics and the ability to evade natural
or vaccine-induced immunity.37 According to
the World Health Organization (WHO), variants of interest (VOI) refers to isolates that
are phenotypically changed when compared to
a reference isolate or genome mutations that
lead to amino acid changes associated with
established or suspected phenotypic implications. VOIs also have been identified to cause
community transmissions with multiple cases
or have been detected in multiple countries
or otherwise assessed to be a VOI by WHO.
WHO also defines variants of concern (VOC) as
VOIs that also demonstrate increased transmissibility, detrimental change in COVID-19
epidemiology, increases in virulence or change
in clinical disease or presentation, or decreases in effectiveness of public health and social
measures, vaccines or therapeutics.38 The CDC
similarly defines VOIs as variants with “specific genetic markers that have been associated
with changes to receptor binding, reduced
neutralization by antibodies generated against
previous infection or vaccination, reduced
efficacy of treatments, potential diagnostic
impact, or predicted increase in transmissibility
or disease severity” and VOCs as those with
“evidence of an increase in transmissibility,
more severe disease (increased hospitalizations
or deaths), significant reduction in neutralization by antibodies generated during previous
infection or vaccination, reduced effectiveness
of treatments or vaccines, or diagnostic detection failures.” The CDC is additionally following
variants of high consequence, which are defined as “having clear evidence that prevention
measures or medical countermeasures have
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significantly reduced effectiveness relative to
previously circulating variants.”39 Currently no
variants are defined under this category. With
the new VOCs arising for SARS-CoV-2, (Figure 2) the question of continued effectiveness
of available vaccines has been raised. Variants
originating from the U.S., UK, South Africa, and
Brazil have all been described.40 The B.1.1.7 variant (UK origin) 20I/501Y.V1 was first reported
in December 2020 and is worrisome due to its
increased transmissibility and increased risk of
hospitalizations and death. The B.1.351 variant
(South Africa origin) 20H/501Y.V2 was first
reported in October 2020 and while there is no
information regarding disease severity, there
is an increased transmissibility and impact on
the neutralization of antibodies. The B.1.1.28.1
variant (Brazil/Japan origin) was also first
described in October 2020 and this variant may
have increased transmissibility and can also
affect antibodies. All three of these variants
were reported in the U.S. by the end of January
2021.39-41
The U.S. has also begun to report its own variants originating internally. A non-peer-reviewed
study detected at least seven home-grown
variants in states across the country. There is a
common single genetic letter mutation among
them; however, they are theorized to have
United Kingdom

Variant: 20I/501Y.V1
Pango lineage: B.1.1.7
First Reported: December
2020
U.S. Reported: Late
December 2020
Uniqueness: Increased risk
of death
Vaccines currently active:
Pfizer-BioNTech
Moderna
AstraZeneca
Janssen/J&J
Novavax
Transmissibility*: Increased
Mortality*: Increased
*As compared to wild type

Of the currently available vaccines, individuals
immunized with mRNA COVID-19 vaccines are
theorized to neutralize the 501 mutations.46
Moderna’s mRNA vaccine has not been affectBrazil/Japan

Variant: 20H/501Y.V2
Pango lineage: B.1.351
First Reported: August
2020
U.S. Reported: Late January
2021
Uniqueness: Neutralization
of polyclonal and
monoclonal antibodies
Vaccines currently active:
Pfizer-BioNTech
Moderna
Janssen/J&J
Transmissibility*: Increased
Mortality*: Unknown

South Africa

Figure 2. SARS-CoV-2 Variants of Concern
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developed independently.41 This study suggests
that in order for the virus to have increased
survival time in human hosts, the strains are
converging toward a common variant.41 Of
note, the emergence of a new variant originating from Southern California (B.1.429/7)
has also been reported.42 This variant has been
in circulation since October 2020 as well and
contains the S protein L452R mutation, which
has previously been found to be resistant to
certain spike protein monoclonal antibodies. A
potential contributor to the rise in resistance
is theorized to be the selective pressure placed
by patients receiving convalescent plasma,
although previous evidence suggests the contrary.43,44 There is also a pressure to immunize
globally, including countries with less resources
to decrease the rates of rising variants as well.
Fortunately, vaccines can be adapted to tackle
variants with modifications to better match
them if needed. The FDA has authorized EUA
addendums rather than full EUA reviews for
vaccines currently approved for use under an
EUA as long as long as the same procedure is
followed.45

Variant: 20J/501Y.V3
Pango lineage: B.1.1.28.1
First Reported: October
2020
U.S. Reported: Late January
2021
Uniqueness: Neutralization
of polyclonal and
monoclonal antibodies
Vaccines currently active:
Pfizer-BioNTech
Moderna
Transmissibility*: Presumed
to be increased
Mortality*: Unknown

Variant: 20C/S:452R
Pango lineage: B.1.429/7
First Reported: October
2020
Uniqueness: Neutralization
of polyclonal and
monoclonal antibodies
Vaccines currently active:
Pfizer-BioNTech
Moderna
Transmissibility*: Increased
Mortality*: Unknown

United States
Southern California

Burgess et al. (2021) 2:2. https://doi.org/10.36518/2689-0216.1269

ed by B.1.1.7 variant but has shown a decreased
efficacy against B.1.351, B.1.1.28.1 and B.1.429/7
variants.47 Pfizer-BioNTech’s mRNA vaccine has
shown decreased efficacy of B.1.1.7, B.1.351 and
B.1.28.1 variants.48 Unfortunately, the campaign
for the AstraZeneca/Oxford vaccine was suspended in South Africa due to ineffectiveness
against the variant (B.1.351) circulating regionally.49 This information comes from a small nonpeer-reviewed study with 2,000 participants
averaging 31 years old that demonstrated only
22% efficacy in South Africa. The Janssen/J&J
vaccine has maintained a higher level of efficacy at about 85% protection against severe
disease for the South African population.
Multiple strategies to combat variants have
been implemented recently. The FDA has
authorized vaccines that have previously received EUA approval to modify their COVID-19
vaccines to target variants without seeking a
separate EUA. This process would allow for
an amendment to the original EUA as long as
the vaccine is made by the same manufacturer and process as the previously authorized
COVID-19 vaccine.45 Pfizer-BioNTech, Moderna
and Johnson & Johnson have all developed
their own strategies in the new battle against
variants. Moderna has focused on updating its
formula to include multivalent vaccines to target variants, while Pfizer-BioNTech has started
their research with booster vaccines. Johnson
& Johnson has focused on modifying their
vaccines to target mutations, which could be a
faster process for vector-based vaccines than
mRNA-based vaccines.50

Safety

While there are many strengths and weaknesses of different types of vaccines, it is important
to note the safety and reactogenicity profiles
of the EUA vaccines are similar. In all three
U.S. approved COVID-19 vaccines, the rates of
serious adverse events were similar in the treatment and placebo groups. For Pfizer-BioNTech,
the overall incidence of any severe systemic
event was 0.6%.9 Mild to moderate injection
site pain experienced seven days after each injection for participants >55 years was 71% after
dose 1 and 66% after dose 2. For participants
16 to 55 years old, the incidence was 83% after
dose 1 and 78% after dose 2.13 Local reactions
were mild to moderate and resolved within
one to two days. With Moderna, the incidence

of any severe systemic event was 0.6%.51 Mild
to moderate injection site pain experienced
seven days after each injection for participants
≥65 years was 74% after dose 1 and 83% after
dose 2. For participants 18 to 64 years old, the
incidence was 87% after dose 1 and 90% after dose 2.10 In comparison, Janssen/J&J, the
only U.S. approved vector vaccine, had a 0.4%
incidence of serious adverse events. Participants experiencing mild to moderate injection
site pain seven days after the injection was
33.3% for participants ≥60 years and 58.6%
for participants aged 18-59 years.17 Although
vaccine adverse event reporting is required in
accordance with each EUA and routine monitoring of this data has been implemented,
little has been reported to the public about this
surveillance.52,53 On April 13, 2021 the CDC and
FDA recommended a pause on administration
of the Janssen/J&J vaccine and issued a Health
Alert Network (HAN) alert to explain the safety
concerns. The alert cited cases of cerebral
venous sinus thrombosis (CVST) with thrombocytopenia after receipt of the Janssen/J&J
vaccine. As of April 12, 2021, there were 6.86
million doses administered and six reports of
CVST with thrombocytopenia following vaccination with Janssen/J&J product. Of these six
cases the median age was 33 years, there was
a median of 8 days for time to symptom onset
and all cases occurred in White females with
no coagulation disorders or obvious patterns of
risk factors.54 The Janssen/J&J vaccine pause
was ended on April 23, 2021 upon completion
of the safety review by the FDA and CDC that
revealed only 15 cases of severe blood clots and
low platelets of the 8 million vaccines administered.55
Data from the Vaccine Adverse Event Reporting System (VAERS) has been reported
for Pfizer-BioNTech and Moderna through
February 16, 2021, when just over 55 million
COVID-19 vaccines had been administered in
the U.S. For the Pfizer-BioNTech vaccine, 48,196
reports were submitted, with 9% deemed to
be a serious adverse event. The most common reported adverse events were headache
(20%), fatigue (15.5%) and dizziness (14.3%).
For Moderna, 56,567 reports have been filed on
behalf of recipients with 3% coded as serious
adverse events. The most common adverse
events were headache (23.4%), pyrexia (18.9%)
and chills (18.3%).53 According to a recent
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JAMA publication, Pfizer-BioNTech anaphylaxis reporting rate is 4.7 cases per million doses
administered, and Moderna anaphylaxis reporting rate is 2.5 cases per million doses administered.56 As of February 16, 2021, most reports
to VAERS among pregnant women involved
non-pregnancy specific adverse events (73%).
Miscarriage was the most frequently reported
pregnancy specific adverse event (15%), but is
comparable to the expected background rate
of the general population (26%).
It is important to know that the CDC’s after
vaccination health checker, V-safe, has enrolled
participants who report pregnancy following
COVID-19 vaccination are actively contacted
to enroll in the pregnancy registry.53 If enrolled,
participants are contacted once per trimester, after delivery and when the infant is three
months old to ask about outcomes of interest
(pregnancy complications, adverse birth outcomes, neonatal death, etc.). As of February 19,
2021, there were 1,815 participants enrolled.57

Equity

There are concerns with ensuring equitable
access to a COVID-19 vaccine for populations at
a disproportionate risk of COVID-19 morbidity
and mortality. A national survey that collected
data from January 6 to January 18, 2021, aimed
to assess data from 67,000 respondents and
found that Black non-Hispanic persons were
52% less likely to report vaccine initiation or
planned vaccination. However, when controlling
for factors (demographic and socioeconomic)
Hispanics and Black non-Hispanics were no
more or less likely than White non-Hispanics to
have received ≥1 dose of a COVID-19 vaccine.58
Ensuring equity in COVID-19 vaccination allocation and distribution has not been forgotten
and is considered in allocation planning. The
Health Resources and Services Administration
(HRSA) and the CDC launched a program early
February to help alleviate potential disparities.59 A limited supply of COVID-19 vaccine
was allocated to select HRSA-funded health
centers. This allocation is separate from those
jurisdictions’ weekly allotment. The health
centers were chosen based on their volume of
serving one of the following disproportionately
affected populations: public housing residents,
migrant/seasonal agricultural workers, patients
with limited English proficiency or individuals
experiencing homelessness. HRSA anticipates
88

that approximately one million doses will be allocated to the program’s initial phase.59 This is a
step in the right direction as federally qualified
health centers serve nearly 30 million patients
each year.58 Vaccinating this population poses
a unique challenge with a two dose vaccination
series and the Janssen/J&J single dose vaccination EUA approval may improve access for
millions of Americans.

Conclusion

There are many moving targets to end this
global pandemic including vaccine availability,
vaccine safety and effectiveness, public opinion
on vaccines, other effective therapeutic treatment options and the rise of variants. However,
one thing is certain, the healthcare community
is working diligently to vaccinate, educate and
provide effective care to all individuals.
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